

Index

A

Absolute quantitation, 171–172
Atherosclerosis, 55–64, 68, 120, 137, 139,
146, 184, 185

B

Bioinformatics, 21–27, 57, 68, 193, 197
Biomarkers, 2, 3, 5, 30, 40, 56–62, 65, 73,
97, 98, 100, 103, 104, 108, 116,
149, 197
Breast cancer, 80, 115, 184

C

Carotid artery stenosis, 56
Cell signaling, 8, 29, 117, 129
Circulation, 21, 25, 30, 31, 40, 45, 48–50, 80,
140, 147
Clinical lipidomics, 1–5
Compliance, 40, 43, 45, 51

D

Disease, 1–5, 8, 16, 22, 31, 40, 49, 55–62, 64,
65, 67, 68, 73, 74, 76, 80, 81, 86–89,
97, 99, 100, 103, 104, 107, 115,
126–128, 138, 141, 145–148, 155,
177–197

E

Environmental exposure, 28–30
Exosome, 98, 101–105
Extracellular vesicle, 182

F

False positives, 155–172
Folic acid (FA), 22–26, 29–32

H

Heart, 11, 21–23, 25, 26, 29–33, 40, 75, 77, 79,
80, 115, 121, 126, 128, 146, 150, 185
Homocysteine (HCy), 22–28, 30, 31
Human, 1, 22–24, 29, 30, 44, 60–62, 74–78,
87, 88, 98, 99, 105, 108, 115, 117, 118,
120, 125–127, 138, 140, 143, 145, 146,
149, 158, 178, 184, 185

I

Immune cell, 74, 76, 81, 84, 87, 89, 147
Ion mobility, 107

L

Lifestyle intervention, 46–47, 49–51
Lipid metabolism, 2, 3, 7–16, 21–34, 48, 51,
63, 65, 77, 82, 83, 85, 115, 150,
183–186
Lipidome, 3, 4, 7, 57, 59, 65–67, 98–105, 155,
156, 158, 192
Lipidomics, 1–5, 57, 97–108, 115, 138,
155–172, 177–197
Lipid profile, 2, 4, 32, 58, 61, 62, 65, 67, 68,
103, 105, 115–116, 118, 124–129
Lipids, 1, 7, 28, 40, 55, 74, 97, 114, 137,
155, 179
Lipiduria, 98
Lung cancer, 4, 5, 7–16

M

Mass spectrometry (MS), 2, 40, 58, 63, 65, 67, 74, 87, 88, 98, 101, 103, 107, 115, 120, 141–145, 155–172, 186–190, 192, 196
Metabolic syndrome (Met S), 39–52, 146
Metabolism, 2, 4, 7–16, 21–34, 41, 44, 48, 58, 62, 63, 65, 74–89, 115, 155, 177, 184, 185
Metabolomics, 61, 73–89, 158, 171
Microarray, 24–26, 28, 29, 33
Mouse embryo, 16, 23, 24, 29, 33
Multivariate data analysis (MVDA), 39–52

O

Oxidation, 12, 14, 29, 73, 77–80, 82–86, 99, 138–141, 143–146, 148, 149, 184, 185, 195

P

Phenomes, 2–5
Phospholipid (PL), 2, 8, 9, 13, 63, 85, 103, 115–117, 119, 121, 125, 126, 138, 140, 141, 144, 145, 147–148, 155–157, 160, 162, 166, 167, 170, 177–197

Phospholipidomics, 177–197

Prognosis, 3, 4, 11, 12, 16, 64, 68, 98, 125, 178

R

Regulation, 1, 2, 4, 8, 15, 23, 29, 31, 32, 48, 51, 64, 74–78, 80–84, 118–123, 126–128

S

Sphingolipids (SL), 2, 9, 13, 40, 60–61, 98, 103, 120, 155, 156, 160, 162, 167

Statistical modelling, 49, 52

U

Untargeted lipidomics, 4, 156, 158–161, 170–172

V

Vascular disease, 8, 16, 55, 57, 58, 60, 141, 148, 155